Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PBZ vs ACTAHIST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PBZ (phenylbutazone) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It also has uricosuric effects.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
FDA-approved for relief of acute gouty arthritis and ankylosing spondylitis,Off-label for rheumatoid arthritis and other inflammatory conditions (rarely used due to toxicity)
Symptomatic relief of allergic rhinitis,Urticaria,Off-label: motion sickness,Off-label: insomnia
25-50 mg orally every 4-6 hours as needed; not to exceed 300 mg/day. For severe allergies: 25 mg intramuscularly or intravenously every 4-6 hours.
1.34 mg (one capsule) orally twice daily.
Terminal elimination half-life: 8-12 hours in adults; prolonged in renal impairment (up to 24 hours).
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Primarily hepatic via CYP450 enzymes (including CYP2C9), with renal excretion of metabolites.
Hepatic metabolism via CYP450 enzymes (primarily CYP3A4 and CYP2D6); major metabolite is inactive.
Renal excretion of unchanged drug (approximately 70-80%) with the remainder as metabolites. Biliary/fecal excretion accounts for <5%.
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
95-98% bound to albumin and alpha-1-acid glycoprotein.
92% bound to albumin.
2-3 L/kg, indicating extensive tissue distribution.
0.9 ± 0.3 L/kg, indicating extensive extravascular distribution.
Oral: 60-70% (first-pass metabolism reduces absolute bioavailability).
Oral: 68% ± 12% due to first-pass metabolism.
No specific guidelines available; use with caution in severe renal impairment (GFR <10 m L/min) due to potential accumulation. Consider dose reduction or increased dosing interval.
No dose adjustment required for mild to moderate renal impairment. Safety not established for severe impairment (GFR <30 m L/min).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor for sedation; Child-Pugh Class C: avoid use due to risk of hepatic encephalopathy or reduce dose by 75%.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C).
Children 2-6 years: 5 mg orally every 4-6 hours, not to exceed 30 mg/day; Children 6-12 years: 10-15 mg orally every 4-6 hours, not to exceed 60 mg/day; Children >12 years: adult dose.
Not indicated for pediatric patients under 12 years of age. Safety and efficacy not established.
Start at 10 mg orally every 6-8 hours; titrate cautiously due to increased sensitivity (sedation, dizziness, anticholinergic effects). Avoid if possible; consider alternative antihistamine with lower anticholinergic burden.
No specific dose adjustment recommended; monitor for increased anticholinergic effects and cognitive impairment.
Risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation; risk of cardiovascular thrombotic events; use is contraindicated for perioperative pain in CABG surgery.
None.
Risk of agranulocytosis, aplastic anemia, and other blood dyscrasias; GI toxicity; cardiovascular events; renal toxicity; hepatic effects; use only when other NSAIDs are ineffective and for short durations; contraindicated in patients with aspirin-sensitive asthma.
May cause drowsiness; caution when driving or operating machinery. Avoid alcohol. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Geriatric patients more sensitive to anticholinergic effects. Pediatric patients <6 years: not recommended.
History of hypersensitivity to NSAIDs; active GI bleeding or peptic ulcer disease; severe hepatic or renal impairment; known coronary artery bypass graft (CABG) surgery; blood dyscrasias.
Hypersensitivity to any component. Newborns or premature infants. Breastfeeding (contraindicated due to risk of adverse effects in infants). Concomitant use with MAOIs.
Avoid concurrent use of alcohol and other CNS depressants. No specific food restrictions, but grapefruit juice has not been studied with this drug. Administer with food if gastrointestinal discomfort occurs.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) if taking MAOIs. Grapefruit juice may increase phenylephrine absorption; limit intake.
PBZ (Piroxicam) is a nonsteroidal anti-inflammatory drug (NSAID). First trimester: Avoid use; associated with increased risk of miscarriage and congenital malformations (e.g., cardiac defects) due to prostaglandin synthesis inhibition. Second trimester: Use only if clearly needed; potential for oligohydramnios and fetal renal dysfunction. Third trimester: Contraindicated; risk of premature closure of ductus arteriosus, persistent pulmonary hypertension, and oligohydramnios.
ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk from vasoconstrictive effects (phenylephrine) possibly reducing uterine blood flow; avoid if possible. Second/third trimester: phenylephrine may cause fetal hypoxia via placental vasoconstriction; use only if benefit outweighs risk. No known structural teratogenicity.
PBZ is excreted into breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.01-0.2. Due to potential adverse effects on infant cardiovascular and renal systems (e.g., platelet dysfunction, renal impairment), use is generally not recommended. Consider alternative analgesics with more established safety profiles.
Brompheniramine is excreted in breast milk in small amounts; M/P ratio not established. Phenylephrine has minimal excretion. Due to anticholinergic effects, may reduce milk production or cause sedation in infants. Use caution; prefer non-sedating alternatives if possible.
Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) may require dose adjustments. However, due to teratogenic risks, PBZ is generally avoided during pregnancy. If use is unavoidable, use the lowest effective dose for the shortest duration, with careful monitoring.
No specific pharmacokinetic studies. Increased plasma volume and renal clearance in pregnancy may reduce drug levels, but efficacy threshold remains. No dose adjustment recommended; use the lowest effective dose for shortest duration due to potential risks.
PBZ (tripelennamine) is a first-generation antihistamine with sedative properties. It is used primarily for allergic conditions and pruritus. Avoid in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Monitor for anticholinergic effects (dry mouth, blurred vision, constipation). May cause paradoxical excitation in children. Dose reduction needed in hepatic impairment.
Actahist is a combination antihistamine-decongestant (chlorpheniramine/phenylephrine). Avoid in patients with hypertension, severe coronary artery disease, or MAOI use. Monitor for sedation and urinary retention, especially in elderly males with BPH.
Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause drowsiness.,Avoid alcohol and other CNS depressants to prevent increased sedation.,Take with food or milk to reduce stomach upset.,Do not crush or chew extended-release tablets; swallow whole.,Contact your doctor if you experience blurred vision, difficulty urinating, or severe constipation.,May cause dry mouth; use sugar-free gum or candy to alleviate.,Store at room temperature away from moisture and heat.,Keep out of reach of children; overdose may cause hallucinations or seizures.
Take with food or milk to reduce stomach upset.,Avoid alcohol and CNS depressants as they can increase drowsiness.,Do not drive or operate machinery until you know how this medication affects you.,Contact your doctor if you experience chest pain, rapid heartbeat, or difficulty urinating.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PBZ vs ACTAHIST, answered by our medical review team.
PBZ is a Antihistamine that works by PBZ (phenylbutazone) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It also has uricosuric effects.. ACTAHIST is a Antihistamine that works by Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PBZ and ACTAHIST depend on the specific clinical indication. These are both Antihistamine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PBZ is: 25-50 mg orally every 4-6 hours as needed; not to exceed 300 mg/day. For severe allergies: 25 mg intramuscularly or intravenously every 4-6 hours.. The standard adult dose of ACTAHIST is: 1.34 mg (one capsule) orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PBZ and ACTAHIST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PBZ is classified as Category C. PBZ (Piroxicam) is a nonsteroidal anti-inflammatory drug (NSAID). First trimester: Avoid use; associated with increased risk of miscarriage and congenital malformations (e.g., card. ACTAHIST is classified as Category C. ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.